-
1Academic Journal
Authors: G. B. Dikke, Г. Б. Дикке
Source: Obstetrics, Gynecology and Reproduction; Vol 16, No 3 (2022); 244-254 ; Акушерство, Гинекология и Репродукция; Vol 16, No 3 (2022); 244-254 ; 2500-3194 ; 2313-7347
Subject Terms: ДЗГ, side effects, breakthrough bleeding, three-phase combined oral contraceptives, COCs, desogestrel, DSG, побочные эффекты, прорывные кровотечения, трехфазные комбинированные оральные контрацептивы, КОК, дезогестрел
File Description: application/pdf
Relation: https://www.gynecology.su/jour/article/view/1349/1020; Schindler A.E., Campagnoli C., Druckmann R. et al. Classification and pharmacology of progestins. Maturitas. 2008;61(1):171–80. https://doi.org/10.1016/j.maturitas.2003.09.014.; Kulier R., Helmerhorst F.M., Maitra N., Gülmezoglu A.M. Effectiveness and acceptability of progestogens in combined oral contraceptives – a systematic review. Reprod Health. 2004;1(1):1–9. https://doi.org/10.1186/1742-4755-1-1.; Hooper D.J. Attitudes, awareness, compliance and preferences among hormonal contraception users: a global, cross-sectional, selfadministered, online survey. Clin Drug Investig. 2010;30(11):749–63. https://doi.org/10.2165/11538900-000000000-00000.; Прилепская В.Н., Назарова Н.М., Тарасова М.А., Летуновская А.Б. Международный проект «CHOICE»: краткий обзор результатов исследования. Гинекология. 2010;12(4):26–8.; Жук С.И., Захурдаева Л.Д. Особенности современного консультирования по вопросам контрацепции. Медицинские аспекты здоровья женщины. 2011;(4):29–32.; Moreau C., Cleland K., Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception. 2007;76(4):267–72. https://doi.org/10.1016/j.contraception.2007.06.008.; Fait T., Buryak D., Cirstoiu M.-M. et al. Needs and preferences of women users of oral contraceptives in selected countries in Central and Eastern Europe. Drugs Context. 2018;7:212510. https://doi.org/10.7573/dic.212510.; Bahamondes L., Pinho F., de Melo N.R. et al. Associated factors with discontinuation use of combined oral contraceptives. Rev Bras Ginecol Obstet. 2011;33(6):303–9. [Article in Portuguese]. https://doi.org/10.1590/s0100-72032011000600007.; Пустотина О.А., Герейбекова Э.Р. Побочные эффекты современных комбинированных оральных контрацептивов. Акушерство и гинекология. Новости. Мнения. Обучение. 2016;(3):96–102.; Мынко О.И., Ашрафзянова Д.Р., Лобанова В.В. Комбинированные оральные контрацептивы: частота применения и возникновения побочных эффектов у женщин репродуктивного возраста. ЭНИГМА. 2020;(26):105–14.; Mack N., Crawford T.J., Guise J.M. et al. Strategies to improve adherence and continuation of shorter-term hormonal methods of contraception. Cochrane Database Syst Rev. 2019;4(4):CD004317. https://doi.org/10.1002/14651858.CD004317.pub5.; Poindexter A. The emerging use of the 20-microg oral contraceptive. Fertil Steril. 2001;75(3):457–6. https://doi.org/10.1016/s0015-0282(00)01747-7.; Edelman A., Micks E., Gallo M.F. et al. Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev. 2014;2014(7):CD004695. https://doi.org/10.1002/14651858.CD004695.pub3.; Gallo M.F., Nanda K., Grimes D.A. et al. 20 µg versus >20 µg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2013;2013(8):CD003989. https://doi.org/10.1002/14651858.CD003989.pub5.; Carr B.R. Cycle control with desogestrel-containing oral contraceptives comparison of a monophasic and triphasic regimen. Int J Fertil Menopausal Stud. 1993;38(5):274–9.; Darney P. Safety and efficacy of a triphasic oral contraceptive containing desogestrel: results of three multicenter trials. Contraception. 1993;48(4):323–37. https://doi.org/10.1016/0010-7824(93)90078-l.; Ferguson H., Vree M.L., Wilpshaar J., Eskes T.K. Multicenter study of the efficacy, cycle control and tolerability of a phasic desogestrel-containing oral contraceptive. Eur J Contracept Reprod Health Care. 2000;5(1):35– 45. https://doi.org/10.1080/13625180008500378.; Coenen C.M., Thomas C.M., Borm G.F. et al. Changes in androgens during treatment with four low-dose contraceptives. Contraception. 1996;53(3):171–6. https://doi.org/10.1016/0010-7824(96)00006-6.; Katz H.I., Kempers S., Akin M.D. et al. Effect of a desogestrel-containing oral contraceptive on the skin. Eur J ContraceptReprod Health Care. 2000;5(4):248–55. https://doi.org/10.1080/13625180008500411.; Prilepskaya V.N., Serov V.N., Zharov E.V. et al. Effects of a phasic oral contraceptive containing desogestrel on facial seborrhea and acne. Contraception. 2003;68(4):239–45. https://doi.org/10.1016/s0010-7824(03)00167-7.; Kränzlin H.T., Nap M.A. The effect of a phasic oral contraceptive containing Desogestrel on seborrhea and acne. Eur J Contracept Reprod Health Care. 2006;11(1):6–13. https://doi.org/10.1080/13625180500252638.; Vartiainen M., de Gezelle H., Broekmeulen C.J. Comparison of the effect on acne with a combiphasicdesogestrel-containing oral contraceptive and a preparation containing cyproterone acetate. Eur J Contracept Reprod Health Care. 2001;6(1):46–53.; van Vloten W.A., van Haselen C.W., van Zuuren E.J. et al. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002;69(4 Suppl):2–15.; De Leo V., Di Sabatino A., Musacchio M.C. et al. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome. Contraception. 2010;82(3):276–80. https://doi.org/10.1016/j.contraception.2010.04.002.; van Vliet H.A., Grimes D.A., Lopez L.M. et al. Triphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev. 2011; 2011(11):CD003553. https://doi.org/10.1002/14651858.CD003553.pub2.; American College of Obstetricians and Gynecologists’ Committee on Health Care for Underserved Women, Contraceptive Equity Expert Work Group, and Committee on Ethic. Patient-Centered Contraceptive Counseling. ACOG Committee Statement Number 1. Obstet Gynecol. 2022;139(2):350–3. https://doi.org/10.1097/AOG.0000000000004659.; Dinger J., Bardenheuer K., Heinemann K. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives. Contraception. 2014;89(4):253–63. https://doi.org/10.1016/j.contraception.2014.01.023.; Kashanian M., Shahpourian F., Zare O. A comparison between monophasic levonorgestrel-ethinyl estradiol 150/30 and triphasic levonorgestrel-ethinyl estradiol 50-75-125/30-40-30 contraceptive pills for side effects and patient satisfaction: a study in Iran. Eur J Obstet Gynecol Reprod Biol. 2010;150(1):47–51. https://doi.org/10.1016/j.ejogrb.2010.01.010.; Roumen F.J. Review of the combined contraceptive vaginal ring, NuvaRing. Ther Clin Risk Manag. 2008;4(2):441–51. https://doi.org/10.2147/tcrm.s1964.; Lawrie T.A., Helmerhorst F.M., Maitra N.K. et al. Types of progestogens in combined oral contraception: effectiveness and side-effects. Cochrane Database Syst Rev. 2011;(5):CD004861. https://doi.org/10.1002/14651858.CD004861.pub2.; Grossman BN. Managing adverse effects of hormonal contraceptives. Am Fam Physician. 2010;82(12):1499–506.; Foran T. The management of irregular bleeding in women using contraception. Aust Fam Physician. 2017;46(10):717–20.; Oral contraceptive-related uterine bleeding management. Family Practice Notebook. Available at: https://fpnotebook.com/Gyn/Pharm/OrlCntrcptvRltdUtrnBldngMngmnt.htm.; Vree M.L., Schmidt J. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany. Eur J Contracept Reprod Health Care. 2001;6(2):108–14.; Дикке Г.Б. Пять шагов к успешной контрацепции. Руководство для врачей. М., 2017. 428 с.; Кузнецова И.В. Метаболические эффекты комбинированной гормональной контрацепции и риск тромботических осложнений. Акушерство и гинекология. 2016;(6):108–14. https://doi.org/10.18565/aig.2016.6.108-114.; Baerwald A.R., Pierson R.A. Ovarian follicular development during the use of oral contraception: a review. J Obstet Gynaecol Can. 2004;26(1):19–24. https://doi.org/10.1016/s1701-2163(16)30692-2/; Bastianelli C., Farris M., Rosato E. et al. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 1. Effects on metabolism. Expert Rev Clin Pharmacol. 2017;10(3):315–26. https://doi.org/10.1080/17512433.2017.1271708.; Lobo R.A., Skinner J.B., Lippman J.S., Cirillo S.J. Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis. Fertil Steril. 1996;65(6):1100–9.; Silva-Bermudez L.S., Toloza F.J.K., Perez-Matos M.C. et al. Effects of oral contraceptives on metabolic parameters in adult premenopausal women: a meta-analysis. Endocr Connect. 2020;9(10):978–98. https://doi.org/10.1530/EC-20-0423.; Godsland I.F., Walton C., Felton C. et al. Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab. 1992;74(1):6470. https://doi.org/10.1210/jcem.74.1.1530790.; Gaspard U., Endrikat J., Desager J.P. et al. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception. 2004;69(4):271–8. https://doi.org/10.1016/j.contraception.2003.11.003.; Adeyanju O.A., Olatunji L.A. Drospirenone-containing oral contraceptives do not affect glucose regulation and circulating corticosterone. J Bas Clinic Physiol Pharm. 2019;30(5):20180184. https://doi.org/10.1515/jbcpp-2018-0184.; Радзинский В.Е., Хамошина М.Б., Абдуллаева Р.Г., Лебедева М.Г. Гормональная контрацепция – лечение и профилактика репродуктивных нарушений у девушек-подростков. Доктор.Ру. 2008;(6):54–8.; https://www.gynecology.su/jour/article/view/1349